Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Matteo Molica · SciRah

Researcher profile · Semantic Scholar

Matteo Molica

Share profile

Matteo Molica — researcher profile on SciRah

h-index: 22
Works: 102
Citations: 1,445

Most-cited papers

Maintenance therapy in AML: The past, the present and the future
Matteo Molica, M. Breccia, R. Foa, E. Jabbour +1 more
2019American journal of hematology/oncology84 citations Open access
Semantic Scholar
Ponatinib: A Review of Efficacy and Safety.
Fulvio Massaro, Matteo Molica, M. Breccia
2017Current Cancer Drug Targets76 citations
Semantic Scholar
TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
Matteo Molica, C. Mazzone, P. Niscola, P. de Fabritiis
2021Frontiers in Oncology66 citations Open access
Semantic Scholar
Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment
M. Breccia, Matteo Molica, I. Zacheo, A. Serrao +1 more
2015Annals of Hematology66 citations
Semantic Scholar
Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)
S. Morano, R. Latagliata, C. Girmenia, Fulvio Massaro +19 more
2015Supportive Care in Cancer62 citations
Semantic Scholar
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
Matteo Molica, S. Perrone, C. Mazzone, P. Niscola +3 more
2021Cancers56 citations Open access
Semantic Scholar
How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
M. Breccia, Matteo Molica, G. Alimena
2014Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis48 citations
Semantic Scholar
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
Matteo Molica, E. Scalzulli, G. Colafigli, R. Foà +1 more
2019Therapeutic Advances in Hematology38 citations Open access
Semantic Scholar
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
M. Breccia, L. Luciano, R. Latagliata, F. Castagnetti +32 more
2014Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis37 citations Open access
Semantic Scholar
SARS‐CoV‐2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies
Matteo Molica, C. Mazzone, I. Cordone, Alessia Pasquale +2 more
2020British Journal of Haematology34 citations Open access
Semantic Scholar
Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).
S. Molica, G. Digiesi, A. Antenucci, L. Levato +7 more
2012Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis32 citations
Semantic Scholar
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.
S. Molica, G. Cutrona, G. Vitelli, R. Mirabelli +5 more
2007Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis31 citations
Semantic Scholar
Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia
S. Molica, G. Digiesi, C. Battaglia, G. Cutrona +7 more
2010European Journal of Haematology28 citations Open access
Semantic Scholar
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis
G. Caocci, O. Mulas, M. Annunziata, L. Luciano +32 more
2018American journal of hematology/oncology27 citations Open access
Semantic Scholar
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
M. Breccia, Matteo Molica, G. Colafigli, Fulvio Massaro +7 more
2017OncoTarget25 citations Open access
Semantic Scholar
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
G. Caocci, O. Mulas, M. Annunziata, L. Luciano +30 more
2019International Journal of Cardiology24 citations Open access
Semantic Scholar
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells
M. Breccia, M. D. De Propris, C. Stefanizzi, Sara Raponi +7 more
2014Annals of Hematology24 citations
Semantic Scholar
Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
Matteo Molica, A. Serrao, Roberta Saracino, I. Zacheo +3 more
2014Annals of Hematology24 citations
Semantic Scholar
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
Matteo Molica, S. Perrone, Marco Rossi
2023Journal of Clinical Medicine22 citations Open access
Semantic Scholar
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
S. Perrone, T. Ottone, Nadezda Zhdanovskaya, Matteo Molica
2023Cancer Drug Resistance22 citations Open access
Semantic Scholar
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option
A. Iurlo, D. Cattaneo, N. Orofino, C. Bucelli +2 more
2018Clinical drug investigation22 citations
Semantic Scholar
Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
Matteo Molica, E. Abruzzese, M. Breccia
2020Mediterranean Journal of Hematology and Infectious Diseases21 citations Open access
Semantic Scholar
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy
L. Cicconi, M. Breccia, L. Franceschini, R. Latagliata +10 more
2018Annals of Hematology21 citations
Semantic Scholar
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
Matteo Molica, E. Scalzulli, G. Colafigli, D. A. Fegatelli +4 more
2018Annals of Hematology21 citations
Semantic Scholar
FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis.
Matteo Molica, M. Breccia
2015Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis19 citations
Semantic Scholar
Systematic review of dasatinib in chronic myeloid leukemia
M. Breccia, Adriano Salaroli, Matteo Molica, G. Alimena
2013OncoTargets and Therapy19 citations Open access
Semantic Scholar
Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.
M. Breccia, Matteo Molica, G. Colafigli, Fulvio Massaro +1 more
2016Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis18 citations
Semantic Scholar
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
M. Breccia, A. Andriani, M. Montanaro, E. Abruzzese +15 more
2017Annals of Hematology17 citations
Semantic Scholar
The Eutos long‐term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials
Matteo Molica, M. Canichella, Danilo Alunni Fegatelli, G. Colafigli +4 more
2017American journal of hematology/oncology17 citations Open access
Semantic Scholar
Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib
M. Breccia, G. Colafigli, Matteo Molica, G. Alimena
2015American journal of hematology/oncology17 citations
Semantic Scholar
Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline.
M. Breccia, E. Arboscello, A. Bellodi, G. Colafigli +7 more
2016Critical reviews in oncology/hematology16 citations
Semantic Scholar
Phase II Study of Cladribine, Idarubicin, and Ara-C (CLIA) with or without Sorafenib as Initial Therapy for Patients with Acute Myeloid Leukemia
T. Kadia, F. Ravandi, Matteo Molica, A. Bataller +20 more
2023American journal of hematology/oncology15 citations Open access
Semantic Scholar
Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia
S. Molica, G. Vitelli, G. Cutrona, K. Todoerti +9 more
2008International journal of hematology15 citations
Semantic Scholar
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML
Matteo Molica, S. Perrone, C. Mazzone, L. Cesini +2 more
2022Cancers14 citations Open access
Semantic Scholar
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia
S. Capria, Matteo Molica, S. Mohamed, S. Bianchi +4 more
2020Expert Review of Hematology14 citations Open access
Semantic Scholar
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
Matteo Molica, G. Colafigli, E. Scalzulli, Danilo Alunni Fegatelli +7 more
2019Annals of Hematology14 citations
Semantic Scholar
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
M. Breccia, D. Bartoletti, M. Bonifacio, G. Palumbo +30 more
2018Annals of Hematology14 citations Open access
Semantic Scholar
Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update
Matteo Molica, Fulvio Massaro, M. Breccia
2017Expert Review of Molecular Diagnostics14 citations
Semantic Scholar
Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia
S. Molica, G. Digiesi, R. Mirabelli, G. Cutrona +8 more
2009European Journal of Haematology14 citations
Semantic Scholar
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks
Matteo Molica, M. Breccia, S. Capria, S. Trisolini +3 more
2019Leukemia and Lymphoma13 citations
Semantic Scholar
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front‐line treatment of a ‘real‐life’ patient population with chronic myeloid leukaemia
R. Latagliata, I. Carmosino, F. Vozella, P. Volpicelli +12 more
2017Hematological Oncology13 citations
Semantic Scholar
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
R. Latagliata, A. Romano, M. Mancini, M. Breccia +11 more
2016Leukemia and Lymphoma13 citations Open access
Semantic Scholar
Drug treatment options for acute promyelocytic leukemia
F. Ferrara, Matteo Molica, M. Bernardi
2021Expert Opinion on Pharmacotherapy12 citations
Semantic Scholar
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
E. Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, G. Colafigli +6 more
2019Annals of Hematology12 citations
Semantic Scholar
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
M. Breccia, G. Colafigli, Matteo Molica, G. Alimena
2016Expert Opinion on Drug Safety12 citations
Semantic Scholar
Long‐term outcome of chronic myeloid leukaemia patients with p210 and p190 co‐expression at baseline
Matteo Molica, I. Zacheo, D. Diverio, G. Alimena +1 more
2015British Journal of Haematology12 citations
Semantic Scholar
Treatment free remission in chronic myeloid leukemia: Lights and shadows
Matteo Molica, N. Noguera, M. Trawinska, G. Martinelli +2 more
2020Hematology Reports11 citations Open access
Semantic Scholar
Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib
R. Latagliata, P. Volpicelli, M. Breccia, F. Vozella +10 more
2015American journal of hematology/oncology11 citations Open access
Semantic Scholar
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
G. Caocci, O. Mulas, E. Abruzzese, A. Iurlo +19 more
2019Annals of Hematology10 citations
Semantic Scholar
How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
Fulvio Massaro, Matteo Molica, M. Breccia
2017Expert Review of Hematology10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Breccia×35
Invite
M. Breccia — researcher profile on SciRah
G. Alimena×15
Invite
G. Alimena — researcher profile on SciRah
R. Latagliata×14
Invite
R. Latagliata — researcher profile on SciRah
R. Foà×13
Invite
R. Foà — researcher profile on SciRah

×12

Invite

G. Colafigli — researcher profile on SciRah

Fulvio Massaro×10

Invite

Fulvio Massaro — researcher profile on SciRah

E. Abruzzese×9

Invite

E. Abruzzese — researcher profile on SciRah

Invite

D. Diverio — researcher profile on SciRah

Invite

A. Iurlo — researcher profile on SciRah

Invite

A. Serrao — researcher profile on SciRah

Invite

G. Binotto — researcher profile on SciRah

Invite

S. Molica — researcher profile on SciRah